Circulating Melan-A/MART-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype

International Journal of Cancer

Volumn 78, Issue 6, 1998, Pages 699-706

  D'Souza, Sushila ^a,d   Rimoldi, Donata ^b   Liénard, Danielle ^a,c   Lejeune, Ferdy ^a   Cerottini, Jean Charles ^b   Romero, Pedro ^b,c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^d PASTEUR INSTITUTE OF BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; HUMAN; LYMPHOCYTE CLONE; MELANOMA; MEMORY CELL; PRIORITY JOURNAL;

ANTIGENS, CD45; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; HLA-A2 ANTIGEN; HUMANS; IMMUNOLOGIC MEMORY; MELANOMA; NEOPLASM PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0031771914     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19981209)78:6<699::AID-IJC6>3.0.CO;2-U     Document Type: Article

References (23)

1. CORMIER, J.N., SALGALLER, M.L., PREVETTE, T., BARRACCHINI, K.C., RIVOLTTNI, L., RESTIFO, N.P., ROSENBERG, S.A. and MARINCOLA, F.M., Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART- 1/Melan-A, Cancer J. Sci. Amer., 3, 37-44 (1997).
2. COULIE, P.G., BRICHARD, V., VAN PEL, A., WOLFEL, T., SCHNEIDER, J., TRAVERSARI, C., MATTEI, S., DE PLAEN, E., LURQUIN, C., SZIKORA, J.P., RENAULD, J.C. and BOON, T., A new gene coding for a differentiation antigen recognized by autologous cytotytic T lymphocytes on HLA-A2 melanomas. J. exp. Med., 180, 35-42 (1994).
3. Cox A.L., SKIPPER, J., CHEN, Y., HENDERSON, R.A., DARROW, T.L., SHABANOWITZ, J., ENGELHARD, V.H., HUNT, D.R and SLINGLUFF JR., C.L., Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science, 264, 716-719(1994).
4. JAGER, E., BERNHARD, HE., ROMERQ, P., RINGHOFFER, M., ARAND, M., KARBACH, L., ILSEMANN, C., HAGEDORN, M. and KNURH A., Generation of cytotoxic T cell responses with synthetic melanoma associated peptides in vivo, implications for tumor vaccines with melanoma associated antigens Int. J. Cancer, 66, 162-169 (1996).
5. KAWAKAMI, Y., ELIYAHU, S., PELGADO, CH., ROBBINS, P.F., SAKAGUCHI, K., APPELLA, E., YANNELLI, J.R., ADEMA, G.J., MIKI, T. and ROSENBERG, S.A., Identification of a human melanoma antigen recognized by tumorinfiltrating lymphocytes associated with in vivo tumor rejection. P roc. nat. Acad. Sci. (Wash.), 91, 6458-6462 (1994a).
6. KAWAKAMI, Y., ELIYAHU, S., JENNINGS, C, SAKAGUCHI, K., KANG, X., SOUTHWOOD, S., ROBBINS, P.F., SETTE, A., APPELLA, E. and ROSENBERG, S.A., Recognition of multiple epitopes in the human melanoma antigen gplOO by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol., 154, 3961-3968 (1995).
7. KAWAKAMI, Y., ELIYAHU, S., SAKAGUCHI, K., ROBBINS, P.F., RIVOLTTNT, L., YANNELLI, J.R., APPELLA, E. and ROSENBERG, S.A., Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. exp. Med., 180, 347-352 (1994b).
8. LEHNER, P.J., WANG, E.G.Y, Moss, P.A.H., WILLIAMS, S., PLATT, K., FRIEDMAN, S.M., BELL, J.L and BORYSIEWICZ, L.K., Human HLA-A0201- restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T, cells bearing the Vβ17 gene segment. J. exp. Med., 181, 79-91 (1995)
9. (27-35) J. exp. Med., 184, 647-657 (1996).
10. MARCHAND, M. and 20 OTHERS, Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer, 63, 883-885 (1995).
11. MARINCOLA, P.M., RIVOLTINI, L., SALGALLER, M.L., PLAYER, T. and ROSENBERG, S.A., Differential anti-MART-1/Melan-A CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors-evidence of in vivo priming by tumor cells. J. Immunoiher., 19, 266-277 (1996).
12. + T cells contain cells with high levels of lymphocyte function-associated antigen-1 expression, a phenotype of primed T cells. J Immunol, 150, 429-437 (1993).
13. RIVOLTINI, L., KAWAKAMI, Y., SAKAGUCHI, K., SOUTHWOOD, S., SETTE, A., ROBBINS, P.P., MARINCOLA, P.M., SALGALLER, M.L., YANNELLI, J.R., APPELLA, E. and ROSENBERG, S.A., Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol., 154, 2257-2265 (1995).
14. ROBBINS, P.P. and KAWAKAMI, Y., Human tumor antigens recognized by T cells. Curr. Opin. Immunol., 8, 628-636 (1996).
15. ROEDERER, M., DUBS, J.G., ANDERSON, M.T., RAJU, P.A. and HERZENBERG, L.A., CDS naive T cell counts decrease progressively in HIV-infected adults. J. clin. Invest., 95, 2061-2066 (1995).
16. ROMERO, P. and 12 OTHERS, Cytolytic T lymphocyte recognition of the immunodominant HLA-A *0201 restricted Melan-A/MART-1 antigenic peptide in melanoma. J. Immunol., 159, 2366-2374 (1997).
17. ROMERO P., PANNETIER, C., HERMAN J., JONGENEEL, C.V., CEROTTINl, J.C. and COULIE, P., Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE1. A1. J. exp. Med., 182, 1019-1028 (1995).
18. + T cell line. J. Immunol., 146, 1175-1183 (1991).
19. SALGALLER, M.L., AFSHAR, A., MARTMCOLA, P.M., RIVOLTINI, L., :KAWAKAMI, Y. and ROSENBERG, S.A., Recognition of multiple epitopes in the human melanoma antigen gpl00 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res., 55, 4972-4979 (1995).
20. SALGALLER, M.L., MARINCOLA, F.M., CORMIER, J.N. and ROSENBERG, S.A., Immunization against epitopes in the human melanoma antigen gplOO following patient immunization with synthetic peptides. Cancer Res., 56, 4749-4757(1996).
21. VALMORI, D., FONTENEAU, J.F., MARANON LIZANA, C., GERVOIS, N., LlENARD, D., RlMOLDI, D., JONGENBEL, C.V., JOTEREAU, F., CEROTTINI, J.C. and ROMERO, R, Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan- A/M ART-1 immunodominant peptide analogs. J. Immunol, 160, 1750-1758 (1998).
22. VAN ELSAS, A., VAN DER BURG, S.H., VAN DER MINNE, C.E., BORGHI, M., MOURER, J.S., MELIEF, C.J.M. and SCHRIER, P.I., Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201 binding peptides from the Melan-A/MART-1 self antigen. Europ. J. Immunol., 26, 1683-1689 (1996).
23. YOUNG, J.L., RAMAGE, J.M., GASTON, J.S.H. and BEVERLEY, P.C.L., In vitro responses of human CD45RO(bright) RA(-) and CD45RO(-) RA(bright) T cell subsets and their relationship to memory and naive T cells. Europ. J. Immunol., 27, 2383-2390 (1997).